ADC Development Pipeline
By using all of the validated and proprietary technology platforms developed at NBE-Therapeutics, we have started to create an early preclinically validated portfolio of ADC product candidates.
In addition to ADCs against established and validated cancer targets, which are either out-licensed already (CD19 and HER-2) or potentially available for out-licensing (CD30), NBE-Therapeutics scientists have developed a preclinically validated portfolio of ADCs in four different cancer target programs, which address a wide variety of hematologic malignancies or solid tumors. Two lead programs are currently undergoing final lead optimization and characterization, and are expected to enter into IND-enabling development and cGMP manufacturing during Q1-2017. The current pipeline and status of NBE-Therapeutics' ADC development candidates is displayed below.
- London, 2019-03-05 - NBE-Therapeutics will present at the 9th World ADC Congress Europe in London
- San Diego, USA, 2019-03-04 - NBE-Therapeutics invited to present at Terrapinn's Americas Antibody Congress
- Basel, 2019-01-29 - Unites States Patent and Trademark Office grants US patent on NBE's linker-toxin technology